Table 5.

Antifungal susceptibilities of multiple C. albicans isolates from each of three episodes of OPC from four HIV-infected patientsa

Patient isolateMIC (μg/ml)
FluconazolebItraconazoleKetoconazoleVoriconazoleSCH 56592Amphotericin BTerbinafine
A
 A.1.10.5<0.0150.06<0.125<0.0150.25>2
 A.1.40.5<0.0150.06<0.125<0.0150.25>2
 A.1.70.5<0.0150.06<0.125<0.0150.25>2
 A.2.1128<0.0150.06<0.125<0.0150.25>2
 A.2.280.1250.25<0.1250.1250.25>2
 A.2.380.1250.250.250.1250.25>2
 A.3.11280.1250.25<0.1250.1250.25>2
 A.3.2320.1250.250.250.1250.25>2
 A.3.316<0.0150.06<0.125<0.0150.125>2
B
 B.1.10.25<0.0150.06<0.125<0.0150.25>2
 B.1.20.5<0.0150.06<0.125<0.0150.125>2
 B.1.54<0.0150.25<0.125<0.0150.25>2
 B.2.28<0.0150.25<0.125<0.0150.25>2
 B.2.44<0.0150.25<0.125<0.0150.25>2
 B.2.580.060.125<0.1250.060.25>2
 B.3.1160.060.125<0.1250.060.25>2
 B.3.44<0.0150.06<0.125<0.0150.25>2
 B.3.5160.060.25<0.1250.060.25>2
C
 C.1.34<0.0150.25<0.125<0.0150.25>2
 C.1.5160.250.50.250.250.25>2
 C.1.10160.1250.25<0.1250.060.25>2
 C.2.1160.060.25<0.1250.060.25>2
 C.2.44<0.0150.25<0.1250.060.25>2
 C.2.880.1250.25<0.125<0.0150.25>2
 C.3.14<0.0150.25<0.125<0.0150.25>2
 C.3.232<0.0150.25<0.125<0.0150.25>2
 C.3.464<0.0150.25<0.1250.060.25>2
D
 D.1.20.5<0.0150.06<0.125<0.0150.252
 D.1.42<0.0150.06<0.125<0.0150.250.5
 D.1.60.25<0.0150.06<0.125<0.0150.251
 D.2.116<0.0150.250.250.030.251
 D.2.21<0.0150.06<0.125<0.0150.1252
 D.2.38<0.0150.25<0.125<0.0150.251
 D.3.12<0.0150.25<0.125<0.0150.125>2
 D.3.3160.1250.250.250.1250.125>2
 D.3.4160.1250.250.250.1250.125>2
  • a Susceptibility was tested with the panel of antifungal drugs shown by a broth microdilution method and by reading of endpoints at 48 h, except as noted.

  • b Fluconazole results are from a broth macrodilution method.